Online citations, reference lists, and bibliographies.
← Back to Search

Subtypes Of Breast Cancer Show Preferential Site Of Relapse.

M. Smid, Y. Wang, Y. Zhang, A. Sieuwerts, J. Yu, J. Klijn, J. Foekens, J. Martens
Published 2008 · Medicine
Referenced 1 time by Citationsy Users

Cite This
Download PDF
Analyze on Scholarcy
Share
We explored whether the five previously reported molecular subtypes in breast cancer show a preference for organ-specific relapse and searched for molecular pathways involved. The "intrinsic" gene list describing the subtypes was used to classify 344 primary breast tumors of lymph node-negative patients. Fisher exact tests were used to determine the association between a tumor subtype and a particular site of distant relapse in these patients who only received local treatment. Modulated genes and pathways were identified in the various groups using Significance Analysis of Microarrays and Global Testing. Bone relapse patients were most abundant in the luminal subtypes but were found less than expected in the basal subtype. The reverse was true for lung and brain relapse patients with the remark that absence of lung relapse was luminal A specific. Finally, a pleura relapse, although rare, was found almost exclusively in both luminal subtypes. Many differentially expressed genes were identified, of which several were in common in a subtype and the site to which the subtype preferentially relapsed. WNT signaling was up-regulated in the basal subtype and in brain-specific relapse, and down-modulated in the luminal B subtype and in bone-specific relapse. Focal adhesion was found up-regulated in the luminal A subtype but down-regulated in lung relapse. The five major molecular subtypes in breast cancer are evidently different with regard to their ability to metastasize to distant organ(s), and share biological features and pathways with their preferred distant metastatic site.
This paper references
10.1038/35065016
Involvement of chemokine receptors in breast cancer metastasis
A. Müller (2001)
10.1186/1471-2407-7-182
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
J. X. Yu (2007)
10.1200/JCO.2005.03.8802
Genes associated with breast cancer metastatic to bone.
M. Smid (2006)
10.1200/JCO.2004.01.072
Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time.
P. Span (2004)
10.1016/S1535-6108(03)00132-6
A multigenic program mediating breast cancer metastasis to bone.
Y. Kang (2003)
10.2307/4615733
A Simple Sequentially Rejective Multiple Test Procedure
S. Holm (1979)
10.1093/bioinformatics/18.11.1462
Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data
L. McShane (2002)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1158/0008-5472.CAN-06-2355
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
T. Hiraga (2007)
10.1038/nm0806-875
Is cancer a disease of self-seeding?
L. Norton (2006)
10.1186/1471-2164-7-96
The molecular portraits of breast tumors are conserved across microarray platforms
Z. Hu (2006)
10.1002/NEU.20166
Morphing into cancer: the role of developmental signaling pathways in brain tumor formation.
M. Fogarty (2005)
10.1073/pnas.0701138104
Lung metastasis genes couple breast tumor size and metastatic spread
A. Minn (2007)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1371/journal.pbio.0020007
Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds
H. Y. Chang (2004)
10.1158/1078-0432.CCR-04-2421
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
R. Rouzier (2005)
maglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high - risk breast cancer
PN Span (2004)
10.1073/pnas.091062498
Significance analysis of microarrays applied to the ionizing radiation response
V. G. Tusher (2001)
10.1093/bioinformatics/bti267
Testing association of a pathway with survival using gene expression data
J. Goeman (2005)
10.1371/journal.pmed.0030047
Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers
Jen-Tsan Chi (2006)
10.1186/1471-2407-6-88
Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies
M. Zafrakas (2005)
KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース)
中尾 光輝 (2000)
10.1200/jco.2004.22.14_suppl.9596
Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer.
P. Ferrucci (2004)
10.1016/S0140-6736(05)17947-1
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Y. Wang (2005)
Is cancer a disease of selfseeding? Nat Med 2006;12:875–8
L Norton (2006)
Target genes of the WNT/h-catenin pathway in Wilms tumors. Genes Chromosomes Cancer 2006;45:565–74
B Zirn (2006)
10.1371/JOURNAL.PBIO.0030187
Determination of Stromal Signatures in Breast Carcinoma
R. West (2005)
The Gene Ontology ( GO ) database and informatics resource Gene Ontology Consortium
Gene Ontology Consortium (2003)
American Association for Cancer cancerres.aacrjournals.org Downloaded from
(2008)
10.1038/75556
Gene Ontology: tool for the unification of biology
M. Ashburner (2000)
The Tumor Suppressor Smad 4 Is Required for Transforming Growth Factor B – Induced Epithelial to Mesenchymal Transition and Bone Metastasis of Breast Cancer Cells
M. Deckers (2006)
10.1182/BLOOD-2005-08-3182
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
J. Burger (2006)
10.1038/nature03799
Genes that mediate breast cancer metastasis to lung
A. Minn (2005)
10.1093/bioinformatics/btg382
A global test for groups of genes: testing association with a clinical outcome
J. Goeman (2004)
10.1158/0008-5472.CAN-06-3322
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers.
S. Winter (2007)
10.1073/pnas.0932692100
Repeated observation of breast tumor subtypes in independent gene expression data sets
T. Sørlie (2003)
10.1073/PNAS.95.25.14863
Cluster analysis and display of genome-wide expression patterns.
M. Eisen (1998)
10.1002/gcc.20319
Target genes of the WNT/β‐catenin pathway in Wilms tumors
B. Zirn (2006)
10.1074/JBC.M306421200
The Human Frizzled 6 (HFz6) Acts as a Negative Regulator of the Canonical Wnt·β-Catenin Signaling Cascade*
T. Golan (2004)
10.1016/S0140-6736(00)49915-0
The distribution of secondary growths in cancer of the breast. 1889.
S. Paget (1989)



This paper is referenced by
10.1080/14737159.2018.1439382
The breast tumor microenvironment: role in cancer development, progression and response to therapy
Suruchi Mittal (2018)
10.1371/journal.pone.0132546
Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness
Gorka Ruiz de Garibay (2015)
10.1038/onc.2015.9
The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis
K. Spring (2015)
Resistance mechanisms during endocrine treatment in breast cancer
Benyamin Ertefai (2016)
10.1007/978-94-007-5291-7_6
Possibilities of Targeted Therapies for Brain Metastasis
Frank Winkler (2012)
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
Preclinical S Tudy (2012)
10.1016/j.celrep.2014.10.011
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor.
Kristen L. Karlin (2014)
10.1016/j.prp.2016.09.007
Clinicopathologic factors associated with de novo metastatic breast cancer.
Tiansheng Shen (2016)
10.1016/j.ejca.2017.08.001
Tumour radiosensitivity is associated with immune activation in solid tumours.
T. Strom (2017)
10.13023/ETD.2019.121
TOWARDS THE RATIONAL DESIGN AND APPLICATION OF POLYMERS FOR GENE THERAPY: INTERNALIZATION AND INTRACELLULAR FATE
Landon Mott (2019)
10.1038/s41467-018-05729-w
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Tyler Risom (2018)
10.1101/399253
Gene co-expression is distance-dependent in breast cancer
D. García-Cortés (2020)
10.5152/tjbh.2016.3247
Background Parenchymal Enhancement and Fibroglandular Tissue Proportion on Breast MRI: Correlation with Hormone Receptor Expression and Molecular Subtypes of Breast Cancer.
M. Öztürk (2017)
10.1371/journal.pone.0184680
New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes
O. Buonomo (2017)
DNA microarrays – future in oncology research and therapy
M. Król (2008)
10.1016/J.PHRS.2020.104683
Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer.
K.G.K. Deepak (2020)
10.1002/JRS.5201
Discrimination of tumor from normal tissues in a mouse model of breast cancer using CARS spectroscopy combined with PC‐DFA methodology
Xi S. Huang (2017)
The Effect of IKKbeta on Estrogen Receptor Positive Breast Cancer Phenotypes
L. El-Shennawy (2015)
Pathway and network analyses in context of Wnt signaling in breast cancer
M. Bayerlová (2016)
10.1080/15384101.2015.1121351
MYC-induced apoptosis in mammary epithelial cells is associated with repression of lineage-specific gene signatures
Heidi M. Haikala (2016)
10.1038/s41556-019-0373-7
Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms
I. S. Kim (2019)
10.1007/s10549-011-1877-4
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
M. Jansen (2011)
10.1158/0008-5472.CAN-15-2306
Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis.
T. Cox (2016)
Breast cancer : brain metastases and treatment aspects
G. Frisk (2019)
10.1016/j.semcancer.2019.10.011
Impact of breast cancer cells´ secretome on the brain metastatic niche remodeling.
R Carvalho (2019)
10.1007/978-1-4939-9164-8_13
Development of a Highly Multiplexed SRM Assay for Biomarker Discovery in Formalin-Fixed Paraffin-Embedded Tissues.
Carine Steiner (2019)
10.18632/oncotarget.27453
Risk factors for breast cancer brain metastases: a systematic review
Lola Koniali (2020)
10.21147/j.issn.1000-9604.2017.03.10
Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance
Tianjian Yu (2017)
10.1158/0008-5472.CAN-08-4135
A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer.
Theresa A. DiMeo (2009)
10.1002/path.2419
Breast cancer special types: why bother?
J. Reis-Filho (2008)
10.1245/s10434-020-08898-5
Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival
C. Dauphine (2020)
Breast cancer progression is modulated by inherited genetic variance in multiple independent cohorts
Szu-Min Hsieh (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar